Indication

Gaucher's disease

Gaucher's disease is a rare, autosomal recessive lysosomal storage disorder caused by mutations in the *GBA1* gene, resulting in deficient activity of the lysosomal enzyme glucocerebrosidase. Read more about Gaucher's disease

12 drugs 10 manufacturers

Advertisement

Drugs that treat it

Common Gaucher's disease therapies.

Showing 10–12 of 12 drugs

MIGLUSTAT

GLUCOSYLCERAMIDE SYNTHASE (GCS) INHIBITORS·GAUCHER'S DISEASE
EDENBRIDGE/DEXC

YARGESA (miglustat)

GLUCOSYLCERAMIDE SYNTHASE (GCS) INHIBITORS·GAUCHER'S DISEASE
EDENBRIDGE/DEXC

MIGLUSTAT

GLUCOSYLCERAMIDE SYNTHASE (GCS) INHIBITORS·GAUCHER'S DISEASE
ZYDUS PHARMACEU
Filter & compare in the drug finder →Opens the drug finder with Gaucher's disease preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Gaucher's disease.

Gaucher's disease is a rare, autosomal recessive lysosomal storage disorder caused by mutations in the *GBA1* gene, resulting in deficient activity of the lysosomal enzyme glucocerebrosidase.

This deficiency leads to the progressive accumulation of glucocerebroside within the mononuclear phagocyte system, generating lipid-laden macrophages (Gaucher cells) primarily in the spleen, liver, and bone marrow.

Clinically, it manifests along a phenotypic spectrum characterized by hepatosplenomegaly, anemia, thrombocytopenia, and skeletal pathology, including bone pain, osteopenia, and avascular necrosis.

The condition can present without primary central nervous system involvement (type 1) or with severe, acute or chronic neuropathic complications (types 2 and 3).

Personalize your experience

Follow Gaucher's disease and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it